Developer docs
API playgroundTry for free, no card

Search company profiles

Healint

Full company profile

uuid000b2dm

Namestring
Healint
Legal namestring
Healint
Websiteurl
healint.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Healint is a Singapore-based digital health company that develops software and connected device solutions for pharmaceutical and biotech companies to support patients with chronic neurological and immunological conditions. Following its February 2024 acquisition by Aptar Digital Health, a division of Aptar Pharma, Healint operates as a subsidiary within Aptar's digital health portfolio, which supports life sciences partners across 120 countries. The company was founded by Francois Cadiou and is led by a team including CTO Nicolas Paris and CMO Suasti Lye.

Short descriptiontext

Healint is a Singapore-based digital health company, acquired by Aptar Digital Health in February 2024, providing pharmaceutical and biotech firms with companion apps, connected drug delivery devices, and Software as a Medical Device solutions for chronic neurological and immunological conditions.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital health platform, companion apps, connected drug delivery, Software as a Medical Device, real-world evidence studies
Industry3 codes
1Therapeutic Companion Apps (Drug-Device-Digital Combination)
CodeHLACANAHPrimaryYes
2Connected Therapeutics & Smart Drug Delivery Monitoring
CodeHLACAFALPrimaryNo
3DTx/SaMD Deployment, Integration & Reimbursement Enablement
CodeHLACANAOPrimaryNo
NAICS code1 code
  • Other Ambulatory Health Care Services6219
SIC code3 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Health Platform
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Digital Health Platform & Solutions
TypeSubscription Recurring
Description

B2B revenue model providing digital health solutions to pharmaceutical and medtech companies including companion apps, connected drug delivery devices, and Software as a Medical Device (SaMD). Solutions support the entire patient journey from treatment initiation to ongoing management.

aptardigitalhealth.com
2Study & Data Services
TypeProfessional Services
Description

Leveraging user communities to run virtual clinical studies and generate real-world evidence on treatment usage for pharmaceutical partners.

aptardigitalhealth.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Migraine Buddy
Description

A mobile application that helps people with migraine and headache disorders track symptoms, triggers, and treatments to better understand and communicate their condition.

aptardigitalhealth.com
Core offering1 text field

Healint builds and operates a certified digital health platform that delivers companion mobile apps (Migraine Buddy, Esme, Allergy Buddy), connected drug-delivery devices (HeroTracker Sense), Software as a Medical Device (SaMD) products, and Study & Data services for pharmaceutical and medtech partners. The platform supports the entire patient journey from treatment initiation through adherence and outcomes, and is used to generate real-world evidence and run virtual clinical studies across 120 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 23.2% CAGR growth projected in digital therapeutics migraine market
+1 more record
Product overview1 text field

Healint was a digital health company focused on neurological conditions, particularly migraine management. Following its acquisition by Aptar Digital Health in February 2024, Healint's flagship product Migraine Buddy became part of Aptar's portfolio of companion apps and digital health solutions. Healint's offerings centered on migraine tracking and symptom management applications designed to help patients understand and communicate their condition to healthcare providers.

Product and service1 record
1Migraine Buddy
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Partnership to integrate Enable Injections' enFuse wearable drug delivery device with Aptar Digital Health's companion digital solution. The collaboration aims to enhance patient experiences by combining connected drug delivery with digital patient engagement capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Collaboration to advance migraine insights by connecting Migraine Buddy app with Oura Ring wearable device. The integration allows users to correlate wearable biometric data with migraine symptoms and triggers for improved understanding and management.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-22
Description

Licensing agreement to develop AI-powered screening algorithms. The partnership leverages AstraZeneca's therapeutic expertise with Aptar Digital Health's digital health platform capabilities to create innovative screening solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Click Therapeutics develops prescription digital therapeutics and software-enhanced drug therapies, primarily through pharma partnerships (e.g., Otsuka). It competes with Healint for enterprise pharma digital health engagements across neurology and other therapeutic areas.

TypeDirect peer
Description

WellDoc develops FDA-cleared digital health platforms and companion apps for chronic conditions (notably diabetes). It serves health systems, payors, and pharma with a regulated SaMD approach comparable to Healint's platform.

TypeDirect peer
Description

Better Therapeutics develops prescription digital therapeutics for cardiometabolic conditions, going through FDA review as a medical device. It pursues a pharma-partnered go-to-market comparable to Healint's companion app and SaMD model.

TypeDirect peer
Description

Happify Health (now Twill) develops digital therapeutics and care platforms for mental health and chronic conditions, with pharma and payor partnerships. It overlaps with Healint on regulated DTx and patient engagement capabilities.

TypeEmerging player
Description

Biofourmis combines remote patient monitoring with AI-driven digital therapeutics, serving pharma and health systems. While its core is RPM-enabled care, its SaMD and pharma partnership motion overlaps with Healint's connected therapeutics and study/data services.

TypeDirect peer
Description

Voluntis is a France-based SaMD platform that develops companion apps and digital therapeutics for oncology, diabetes, and other conditions, partnering with pharma companies. It is a direct peer to Healint and is now also part of Aptar Digital Health following its acquisition, making it the closest sibling in the portfolio.

TypeDirect peer
Description

Sidekick Health is a digital therapeutics platform offering condition-specific companion apps across multiple therapeutic areas through partnerships with pharma and payors. It directly competes with Healint for pharma digital engagement contracts and therapeutic-area breadth.

TypeDirect peer
Description

Kaia Health develops digital therapeutics for musculoskeletal pain and chronic conditions, with employer and payor channels alongside pharma engagement. Its DTx focus on pain/MSK overlaps thematically with Healint's neurological chronic-condition portfolio.

TypeDirect peer
Description

Akili Interactive is a prescription digital therapeutics company focused on cognitive neurology (ADHD, multiple sclerosis cognitive dysfunction). It serves pharma through prescription DTx distribution and partnership models similar to Healint's pharma enterprise motion.

TypeDirect peer
Description

Medisafe is a medication adherence companion app platform with pharma partnerships. Its focus on adherence tracking and patient engagement for chronic conditions overlaps directly with Healint's Migraine Buddy and companion app offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Healint

Digital Health Platformhealint.com

Healint is a Singapore-based digital health company, acquired by Aptar Digital Health in February 2024, providing pharmaceutical and biotech firms with companion apps, connected drug delivery devices, and Software as a Medical Device solutions for chronic neurological and immunological conditions.

What Healint does

Healint is a Singapore-based digital health company that develops software and connected device solutions for pharmaceutical and biotech companies to support patients with chronic neurological and immunological conditions. Following its February 2024 acquisition by Aptar Digital Health, a division of Aptar Pharma, Healint operates as a subsidiary within Aptar's digital health portfolio, which supports life sciences partners across 120 countries. The company was founded by Francois Cadiou and is led by a team including CTO Nicolas Paris and CMO Suasti Lye.

Healint firmographics

Firmographics
Name
Healint
Legal name
Healint
Website
https://healint.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
Healint is a Singapore-based digital health company, acquired by Aptar Digital Health in February 2024, providing pharmaceutical and biotech firms with companion apps, connected drug delivery devices, and Software as a Medical Device solutions for chronic neurological and immunological conditions.
Ownership category
akta.pro rank

Healint industry classification

Industry
Product category
Digital Health Platform
NAICS
Other Ambulatory Health Care Services (6219)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
akta.pro secondary industries
Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

Keywords

  • Digital health platform
  • Companion apps
  • Connected drug delivery
  • Software as a Medical Device
  • Real-world evidence studies

Where Healint is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Healint business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Digital Health Platform & Solutions: B2B revenue model providing digital health solutions to pharmaceutical and medtech companies including companion apps, connected drug delivery devices, and Software as a Medical Device (SaMD). Solutions support the entire patient journey from treatment initiation to ongoing management.
  2. Study & Data Services: Leveraging user communities to run virtual clinical studies and generate real-world evidence on treatment usage for pharmaceutical partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Healint product offering

Product offering

Core offering

Healint builds and operates a certified digital health platform that delivers companion mobile apps (Migraine Buddy, Esme, Allergy Buddy), connected drug-delivery devices (HeroTracker Sense), Software as a Medical Device (SaMD) products, and Study & Data services for pharmaceutical and medtech partners. The platform supports the entire patient journey from treatment initiation through adherence and outcomes, and is used to generate real-world evidence and run virtual clinical studies across 120 countries.

Product overview

Healint was a digital health company focused on neurological conditions, particularly migraine management. Following its acquisition by Aptar Digital Health in February 2024, Healint's flagship product Migraine Buddy became part of Aptar's portfolio of companion apps and digital health solutions. Healint's offerings centered on migraine tracking and symptom management applications designed to help patients understand and communicate their condition to healthcare providers.

Differentiator

Problem solved

Functional benefit

Brands

  • Migraine Buddy: A mobile application that helps people with migraine and headache disorders track symptoms, triggers, and treatments to better understand and communicate their condition.

Products and services

  • Migraine Buddy

Quantifiable outcome

  • 23.2% CAGR growth projected in digital therapeutics migraine market
  • +1 more outcomes

Companies that use Healint

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Healint technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Healint partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Enable InjectionscoreStrategic or Co-development Partner · 9 April 2026Partnership to integrate Enable Injections' enFuse wearable drug delivery device with Aptar Digital Health's companion digital solution. The collaboration aims to enhance patient experiences by combining connected drug delivery with digital patient engagement capabilities.
  • ŌURAcoreTechnology or Integration · 7 January 2026Collaboration to advance migraine insights by connecting Migraine Buddy app with Oura Ring wearable device. The integration allows users to correlate wearable biometric data with migraine symptoms and triggers for improved understanding and management.
  • AstraZenecacoreStrategic or Co-development Partner · 22 May 2025Licensing agreement to develop AI-powered screening algorithms. The partnership leverages AstraZeneca's therapeutic expertise with Aptar Digital Health's digital health platform capabilities to create innovative screening solutions.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Healint competitors and assessment

Company assessment

Direct peers

  • Click Therapeutics: Click Therapeutics develops prescription digital therapeutics and software-enhanced drug therapies, primarily through pharma partnerships (e.g., Otsuka). It competes with Healint for enterprise pharma digital health engagements across neurology and other therapeutic areas.
  • WellDoc: WellDoc develops FDA-cleared digital health platforms and companion apps for chronic conditions (notably diabetes). It serves health systems, payors, and pharma with a regulated SaMD approach comparable to Healint's platform.
  • Better Therapeutics: Better Therapeutics develops prescription digital therapeutics for cardiometabolic conditions, going through FDA review as a medical device. It pursues a pharma-partnered go-to-market comparable to Healint's companion app and SaMD model.
  • Happify Health: Happify Health (now Twill) develops digital therapeutics and care platforms for mental health and chronic conditions, with pharma and payor partnerships. It overlaps with Healint on regulated DTx and patient engagement capabilities.
  • Voluntis: Voluntis is a France-based SaMD platform that develops companion apps and digital therapeutics for oncology, diabetes, and other conditions, partnering with pharma companies. It is a direct peer to Healint and is now also part of Aptar Digital Health following its acquisition, making it the closest sibling in the portfolio.
  • Sidekick Health: Sidekick Health is a digital therapeutics platform offering condition-specific companion apps across multiple therapeutic areas through partnerships with pharma and payors. It directly competes with Healint for pharma digital engagement contracts and therapeutic-area breadth.
  • Kaia Health: Kaia Health develops digital therapeutics for musculoskeletal pain and chronic conditions, with employer and payor channels alongside pharma engagement. Its DTx focus on pain/MSK overlaps thematically with Healint's neurological chronic-condition portfolio.
  • Akili Interactive: Akili Interactive is a prescription digital therapeutics company focused on cognitive neurology (ADHD, multiple sclerosis cognitive dysfunction). It serves pharma through prescription DTx distribution and partnership models similar to Healint's pharma enterprise motion.
  • Medisafe: Medisafe is a medication adherence companion app platform with pharma partnerships. Its focus on adherence tracking and patient engagement for chronic conditions overlaps directly with Healint's Migraine Buddy and companion app offerings.

Emerging players

  • Biofourmis: Biofourmis combines remote patient monitoring with AI-driven digital therapeutics, serving pharma and health systems. While its core is RPM-enabled care, its SaMD and pharma partnership motion overlaps with Healint's connected therapeutics and study/data services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Healint social profiles

Digital presence

Healint financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Healint leadership team

Management profile

Number of profiles

Profiles4 records

Healint funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Healint M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healint

What does Healint do?

Healint builds and operates a certified digital health platform that delivers companion mobile apps (Migraine Buddy, Esme, Allergy Buddy), connected drug-delivery devices (HeroTracker Sense), Software as a Medical Device (SaMD) products, and Study & Data services for pharmaceutical and medtech partners. The platform supports the entire patient journey from treatment initiation through adherence and outcomes, and is used to generate real-world evidence and run virtual clinical studies across 120 countries.

Is Healint a public or private company?

Healint is a private company. It is classified as corporate owned and is currently acquired.

When was Healint founded?

Healint was founded in 2015. It employs 11 to 50 people.

Where is Healint based?

Healint is headquartered in Singapore, Singapore, in the Asia region.

How does Healint make money?

Two revenue lines are on record. Digital Health Platform & Solutions are the primary driver. The others are study & Data Services.

Who are Healint's main competitors?

Direct peers on record are Click Therapeutics, WellDoc, Better Therapeutics, Happify Health, Voluntis, Sidekick Health, Kaia Health, Akili Interactive and Medisafe. Biofourmis is listed as an emerging player.

Does Healint have an API?

No public API is recorded for Healint.

What industry is Healint in?

Healint's product category is Digital Health Platform. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 6219 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comFuture Perspectives: Key Trends Shaping the Digital Health Market Until 2029The digital health market is projected to grow significantly, reaching $580.86 billion by 2029, driven by increasing chronic disease cases and an aging population. Key companies in this market include Aptar Digital Health, which recently acquired Healint, a digital health tool provider focused on neurological disorders. Innovations such as augmented reality and AI are anticipated to reshape healthcare services in the coming years.Grand View ResearchU.S. Digital Health Market Size, ShareThe U.S. digital health market was estimated at USD 81.17 billion in 2023 and is projected to grow at a CAGR of 19.5% to reach USD 276.62 billion by 2030, driven by increasing smartphone penetration, 5G adoption, and AI/ML integration in healthcare. The telehealthcare segment held the largest revenue share of 43.2% in 2023, while the diabetes application segment accounted for over 24.3% of market share. Notable recent developments include Aptar Digital Health's acquisition of Healint in February 2024, Samsung Electronics receiving FDA De Novo approval for its sleep apnea feature, and various strategic partnerships and product launches by major technology and healthcare companies.IncubeesSingapore healthcare firm Healint acquired by Aptar Digital Health – IncubeesAptar Digital Health acquired the Singapore-based digital health company Healint as part of its strategy to expand its neurology portfolio and enhance its global presence in digital health solutions. The acquisition allows Aptar to improve its offerings in clinical trial management, patient community management, and digital diagnostics. With this integration, Aptar Digital Health aims to position itself as a leader in digital health for Central Nervous System conditions.PR NewswireHealint announces a collaboration with Saitama Medical University Hospital, Japan, to verify AI diagnosis of MigraineSaitama Medical University Hospital and Healint launched a clinical study titled "Verification of Headache AI diagnosis by using Electronic Headache Diary in Telemedicine," involving about 20 headache specialists in Japan recruiting patients from late April 2023. The study aims to validate how Healint's AI-powered Migraine Buddy platform can support doctors in diagnosing migraine patients, addressing the fact that diagnosis and treatment rates among non-specialists remain below 20% despite 30 million chronic headache patients in Japan. Results from the study, which leverages data from over 3.5 million Migraine Buddy users worldwide, are expected to be published soon after completion.PR NewswireWorld-First, 45,000 patients study to develop AI-based "precision medicine" for migraine relief - collaboration between Healint and University of Geneva, SwitzerlandHealint, the developer of the Migraine Buddy platform with over 3 million users, has announced a collaboration with the University of Geneva to conduct a world-first study analyzing data from 45,000 Migraine Buddy volunteers, comprising nearly 1 million migraine attack events across 69 dimensions. The study aims to develop AI-based precision medicine for migraine relief by predicting treatment efficacy based on individual patient characteristics and modeling migraine disease progression using Markov chains. The research will examine triggers, self-reported pain levels, and contextual factors like sleep and weather to support personalized medication recommendations.PR NewswireNestle Health Science Partners with Healint to Initiate a Fully Virtual Study on Ketogenic Treatment for MigrainesNestlé Health Science has initiated a fully virtual randomized clinical trial in Quebec, Canada, to evaluate the effectiveness of a ketogenic nutritional supplement in reducing the number, intensity, and duration of migraines in people with episodic migraines. The five-month study, conducted entirely remotely with no clinical site visits, uses Healint's Migraine Buddy app platform for participant screening, recruitment, and real-time tracking, marking Nestlé's first randomized clinical trial for central nervous system conditions conducted fully virtually. The partnership aims to improve patient accessibility to clinical trials while reducing costs through digital technology and lowering barriers for qualified participants.PR NewswireEmpowering Patients To Manage Their Chronic Conditions With The Establishment Of The Scientific Advisory Board By HealintHealint has established a Scientific Advisory Board comprising international clinician-scientists to guide the company's initiatives in decentralized clinical trials and real-world evidence studies. The board is chaired by Prof. David Dodick and aims to empower patients in managing chronic conditions like migraines through innovative technology. Healint seeks to enhance its global outreach and clinical care for patients suffering from chronic pain diseases.PR NewswireHealint Starts Third Virtual Clinical Trial Amid COVID-19 PandemicHealint has begun recruiting patients for its third virtual global clinical trial, focusing on ePRO measures for an acute migraine medication amidst the ongoing pandemic. The company leverages its Migraine Buddy app, which has over 2.5 million users, to facilitate remote data collection and reduce the costs and inefficiencies associated with traditional in-person trials. Recruitment is scheduled to conclude by the third quarter of 2021, with the trial expected to last eight to twelve months.PR NewswireNew Study Reveals 30% of Migraine Sufferers in America Have Tried Cannabis For Migraine ReliefHealint, a healthcare technology company, released a study on September 23, 2020 finding that 30 percent of migraine patients in the U.S. have used cannabis to relieve migraine pain, with 82 percent of those users reporting it effective in reducing pain levels. The study surveyed 9,885 Migraine Buddy app users in the U.S. and Canada, with Healint CEO Francois Cadiou noting that expanding state-level legalization of medical marijuana is increasing patient awareness of cannabis as a migraine treatment option. Medical experts cited in the article called for more rigorous research on proper dosage and administration methods for cannabis-based migraine treatment.PR NewswireCOVID-19 Causing Hidden Health ImpactsHealint, a Singapore-based healthcare technology company and developer of the Migraine Buddy tracking app, released research showing that COVID-19 has increased migraine frequency and stress-related migraine attacks, with data analyzed from over 300,000 app users and nearly 2.5 million migraine attacks between December 2019 and July 2020. The findings indicate that stress-related migraine attacks were 30 to 50 percent higher than during the 2019 holiday season, while 61 percent of surveyed migraine sufferers reported more frequent migraines since the pandemic began. Healint CEO Francois Cadiou noted that migraine sufferers will need to manage stress proactively as the United States faces potential second-wave scenarios.